Holen Sie sich die Stockscreener-App
0.3437
1.21%
-0.0042
Handel nachbörslich:
.34
-0.0037
-1.08%
Schlusskurs vom Vortag:
$0.3479
Offen:
$0.348
24-Stunden-Volumen:
26,558
Relative Volume:
0.05
Marktkapitalisierung:
$1.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+4.15%
1M Leistung:
-20.99%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.3392
$0.352
1-Wochen-Bereich:
$0.31
$0.36
52-Wochen-Spanne:
$0.185
$3.00
Entero Therapeutics Inc Stock (ENTO) Company Profile
Firmenname
Entero Therapeutics Inc
Sektor
Branche
Telefon
561-589-7020
Adresse
777 YAMATO ROAD, BOCA RATON
Entero Therapeutics Inc Aktie (ENTO) Neueste Nachrichten
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
EMCOR Group (NYSE:EME) Sets New 12-Month High at $402.91 - Defense World
Evolus (NASDAQ:EOLS) Trading Down 2.9% - Defense World
Health Beat: Hope for children with EoE - 69News WFMZ-TV
Emmaus Life Sciences director buys $800 in company stock By Investing.com - Investing.com UK
Debt-Free Multibagger Stock Hit 18 Consecutive Upper Circuits & 52-Week Highs: Will the Rally Come to a Halt? - Dalal Street Investment Journal
EMCOR Group (NYSE:EME) Hits New 1-Year High at $402.91 - MarketBeat
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics faces Nasdaq delisting over share price - Investing.com
Entero Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Canoo Inc (NASDAQ: GOEV) Could Pass $4.5 In One Year Stock Forecast - Stocks Register
Understanding ENTO stock ratios for better investment decisions - US Post News
Entero Therapeutics Secures Exclusive Technology License - Investing.com
Entero Therapeutics Secures Exclusive Technology License By Investing.com - Investing.com Canada
Entero Therapeutics signs letter of intent with Data Vault Holdings - TipRanks
Entero Therapeutics Signs Letter of Intent to License and - GlobeNewswire
Entero Therapeutics appoints new independent accountant - Investing.com India
Entero Therapeutics appoints new independent accountant - Investing.com
Entero Therapeutics appoints new independent accountant By Investing.com - Investing.com Canada
Entero Therapeutics, Inc. (NASDAQ:ENTO) Short Interest Up 666.0% in August - Defense World
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - GlobeNewswire
Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q - Yahoo Finance
Entero Therapeutics appoints new Audit Committee member - Investing.com India
Entero Therapeutics appoints new Audit Committee member - Investing.com
180 Life Sciences (NASDAQ:ATNF) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics appoints new Audit Committee member By Investing.com - Investing.com UK
ENTO’s 2023 Market Dance: Down -90.00% – Time to Invest? - The InvestChronicle
Monitoring Entero Therapeutics Inc. (ENTO) after recent insider movements - Knox Daily
ENTO (Entero Therapeutics) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
Bone Biologics (NASDAQ:BBLG) Stock Quotes, Forecast and News Summary - Benzinga
Entero Therapeutics appoints new board member - Investing.com
A Look at Entero Therapeutics Inc. (ENTO) Shares in the Recent Past Indicates Growth - SETE News
Enovix Corporation [ENVX] moved down -5.82: Why It’s Important - The DBT News
why Entero Therapeutics Inc. [ENTO] is a Good Choice for Investors After New Price Target of $36.00 - The DBT News
Entero Therapeutics Inc.’s latest rating changes from various analysts - Knox Daily
Kraft Heinz Co [KHC] is -7.60% lower this YTD. Is it still time to buy? - The DBT News
For Regions Financial Corp. [RF], Analyst sees a rise to $23. What next? - The DBT News
Market Analysts see HP Inc [HPQ] gaining to $32. Time to buy? - The DBT News
Market Momentum: Entero Therapeutics Inc. (ENTO) Registers a 19.06 Increase, Closing at 0.28 - The Dwinnex
PDD’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
A Tale of Resilience: Entero Therapeutics Inc. Amid Stock Market Turbulence - The InvestChronicle
Company’s Banking Stock: Dissecting a -34.75% Quarterly Revenue Decline Amid Growth - The InvestChronicle
The Psychology of Red Cat Holdings Inc Inc. (RCAT) Price Performance: Understanding Market Sentiment - The InvestChronicle
Energy Transfer LP (ET) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Investing in Entero Therapeutics Inc. (ENTO) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray - RTTNews
Closing Bell Recap: Entero Therapeutics Inc. (ENTO) Ends at 0.24, Reflecting a -61.85 Downturn - The Dwinnex
Arhaus Inc [ARHS] stock Initiated by Stifel analyst, price target now $19.50 - The DBT News
Entero Therapeutics Inc. [ENTO] Revenue clocked in at $0.00 million, down -94.34% YTD: What’s Next? - The DBT News
United States shares higher at close of trade; Dow Jones Industrial Average up 1.76% - Investing.com India
Wall Street Analyst Initiated Celestica, Inc. [CLS]. What else is Wall St. saying - The DBT News
Finanzdaten der Entero Therapeutics Inc-Aktie (ENTO)
Es liegen keine Finanzdaten für Entero Therapeutics Inc (ENTO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Entero Therapeutics Inc-Aktie (ENTO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SAPIRSTEIN JAMES | Chairman and CEO |
Jul 02 '24 |
Sale |
1.07 |
1,289 |
1,379 |
35,816 |
| SAPIRSTEIN JAMES | Chairman and CEO |
Apr 01 '24 |
Sale |
4.23 |
174 |
736 |
37,105 |
| Romano Sarah | Chief Financial Officer |
Apr 01 '24 |
Sale |
4.23 |
75 |
317 |
19,111 |
| SAPIRSTEIN JAMES | Chairman and CEO |
Mar 15 '24 |
Sale |
4.96 |
1,887 |
9,360 |
37,279 |
| Romano Sarah | Chief Financial Officer |
Mar 15 '24 |
Sale |
4.96 |
1,120 |
5,555 |
19,186 |
| Romano Sarah | Chief Financial Officer |
Jan 12 '24 |
Sale |
4.20 |
98 |
412 |
20,306 |
| SAPIRSTEIN JAMES | Chairman, President and CEO |
Jan 12 '24 |
Sale |
4.20 |
166 |
697 |
39,166 |
| Romano Sarah | Chief Financial Officer |
Oct 04 '23 |
Sale |
0.29 |
1,676 |
486 |
15,800 |
| SAPIRSTEIN JAMES | President and CEO |
Oct 04 '23 |
Sale |
0.29 |
2,764 |
802 |
33,397 |
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):